



**What the eye doesn't
see in molecular
interactions:
*a virtual microscope to
understand
cyclodextrins***

Rebeca García Fandiño
CSO at MD.USE Innovations
CiQUS-Santiago de Compostela University (Spain)
rebeca.garcia.fandino@usc.es




Characterization of molecular interactions: Molecular Dynamics & ITC experiments

3D, VR, AR & 3D-printing for Research and Dissemination

www.mduse.com info@mduse.com [@md_use](https://twitter.com/md_use)



- Molecular Dynamics simulations studies, executed at supercomputer centers
- Isothermal Titration Calorimetry (ITC): experiments and analyses
- Software development for immersive visualization of molecules in Augmented and Virtual reality








WHAT THE EYES DOESN'T SEE...THE COMPUTER DOES!




- Atomic resolution
- Explicit solvent
- Structural-dynamic information
- Supercomputer dependence





WHAT THE EYES DOESN'T SEE...ITC CAN MEASURE!



AFFINOMETER FOR ISOTHERMAL TITRATION CALORIMETRY

AFFINOMETER

Available in the Cloud and for Windows (64-bit)



- Get the full kinetic and thermodynamic profiles of interactions.
- Generate tailored binding models.
- Perform global analysis of multiple ITC isotherms.

[Learn more](#)

Partners of

AFFINOMETER




AFFINOMETER FOR SPECTROSCOPIC TECHNIQUES

- Easy upload of binding curves from different techniques into the same fitting project.
- Perform a global analysis of multiple data generated from different frequencies of the spectra in a titration experiment or from different techniques.
- Use advanced binding models for the analysis of complex interactions.

[Learn more](#)


[Get a free trial](#)






Nanocarriers

Proteins and peptides



Lipid membranes


DNA and RNA



Carbon nanotubes

**EXCIPIENTS
(Cyclodextrins)**


Polymers




Sugars



WHAT ARE CYCLODEXTRINS?






Cyclodextrins (CDs) are **excipients** which can influence the properties (such as toxicity, stability, solubility or skin penetration) of the active substance and other medicines.







THE “CYCLODEXTRIN PARADOX”



Almost any drug in the market has gone, at least in any step of its development, through a **computational modelling process**, saving to this sector a lot of money and time in their R&D process.

Typical for **protein + drug...** but what happens to **cyclodextrins**?

Computational tools are **scarcely used** in **cyclodextrin** industry...! ...despite the elements implied in the process (receptor + ligand = CD + guest), are analogous to those typically implicated in the pharmaceutical industry.






MOLECULAR DYNAMICS SIMULATIONS WITH CYCLODEXTRINS

Starting Conformation

Final Conformation





P. Brocos, N. Díaz-Vergara, X. Banquy, S. Pérez-Casas, M. Costas, A. Piñeiro. *J. Phys. Chem. B* **2010**, *114*, 12455.

Cyclo-lib: A database of computational molecular dynamics simulations of cyclodextrins

<http://cyclo-lib.mduse.com/>



E. Mixcoha, R. Rosende, R. Garcia-Fandino, A. Piñeiro *Bioinformatics* **2016**, *32* (21), 3371.





P. F. Garrido, M. Calvelo, R. Garcia-Fandiño, Á. Piñeiro, *Biomolecules* **2020**, *10* (3), 431.



MOLECULAR DYNAMICS SIMULATIONS WITH CYCLODEXTRINS



J. Hernández, C. Garza, X. Banquy, N. Díaz, A. Amigo, S. Ramos, R. Castillo, M. Costas, Á. Piñeiro. *J. Phys. Chem. B*, **2007**, 111, 12625. P. Brocos, X. Banquy, N. Díaz, S. Pérez, Á. Piñeiro, M. Costas. *J. Phys. Chem. B*, **2011**, 115, 14381.



I. The encapsulating Army

Excipients for antiviral drugs

II. Collaborative weapons

Stabilizers or co-drugs

III. Using the ring as a direct weapon

Modified CDs as antiviral drugs

IV. Sentinels to prevent invasions

CDs in antiviral vaccines

V. Trying to break the enemy's borders

Cholesterol trappers to damage the viral capsid membrane

VI. Intercepting messages of the enemy

CD in RNA therapies

VII. Blood on the battlefield

CDs as anticoagulant agents



International Journal of Pharmaceutics


Volume 588, 15 October 2020, 119689



The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2

Dedicated to Prof. Thorsteinn Loftsson, one of the greatest Nanoring Lords, in his 70th birthday.

Pablo F. Garrido ^a, Martín Calvelo ^b, Alexandre Blanco-González ^b, Uxía Veleiro ^a, Fabián Suárez ^a, Daniel Conde ^b, Alfonso Cabezón ^b, Ángel Piñeiro ^a , Rebeca Garcia-Fandino ^b 




THE LORD OF THE NANORINGS: cyclodextrins and the battle against SARS-CoV-2

CICLODEXTRINAS EN LA FORMULACIÓN DEL REMDESIVIR



Ligand's Captisol Technology Plays Key Role in the Manufacture of Gilead's Veklury, the First FDA-Approved COVID-19 Treatment

Ligand

CAPTISOL
A Ligand TECHNOLOGY



 **MD.USE**
Innovative Solutions S.L.



Piñeiro, A.; Pipkin, J.; Antle, V.; Garcia-Fandino, R. "Do the substitution pattern of modified cyclodextrins affect the encapsulation of drugs? A case study using sulphobutylether-b-cyclodextrin and remdesivir" sent to International Journal of Pharmaceutics **2020**



CAPTISOL

CAPTISOL®

A Ligand TECHNOLOGY

Captisol Electropherogram






Figure 2 How Captisol Works



Nexterone
(amiodarone HCl)

VFEND
(voriconazole)

GEODON
(liprazone HCl)

Baxter International

Pfizer

Pfizer

Cerenia
(maropitant citrate)

Kyprolis
(carfilzomib) injection

EVOMELA
(melphalan) for Injection

Pfizer

Amgen

Acrotech

NOXAFIL
(posaconazole)
Injection 10mg/mL

Carnexiv
(carbamazepine) injection
Continuity counts.

Baxdela
(delafloxacin) 300 mg capsules

Merck

Lundbeck

Baxdela

Veklury
(remdesivir)
100 mg/mL for Injection

Gilead

FDA-Approved Captisol-enabled® Drugs








CAPTISOL + REMDESIVIR: AN ORTHOGONAL STUDY

Molecular Dynamics simulations





Captisol:Remdesivir (10:1 to 30:1)






CAPTISOL + REMDESIVIR: AN ORTHOGONAL STUDY

Molecular Dynamics simulations






Potential of Mean Force calculations





CAPTISOL + REMDESIVIR: AN ORTHOGONAL STUDY





Molecular Dynamics simulations





CAPTISOL + REMDESIVIR: AN ORTHOGONAL STUDY

Molecular Dynamics simulations





CAPTISOL + REMDESIVIR: AN ORTHOGONAL STUDY

Molecular Dynamics simulations

Equilibrium constant: $A + B \rightleftharpoons C$: $K_{eq} = \frac{q_C/V}{q_A/V q_B/V}$ (V is the volume of the system)

No internal degrees of freedom for A and B

$$H_A = \sum_{i=1}^3 \frac{p_i^2}{2m_A}; \quad H_B = \sum_{i=1}^3 \frac{p_i^2}{2m_B}$$

$$q_A = V(2\pi m_A k_B T / h^2)^{3/2}$$

$$q_B = V(2\pi m_B k_B T / h^2)^{3/2}$$

Si $U=U(r) \Rightarrow$ spherical symmetry

Reference state $\Rightarrow$ 1 M concentration
(since U only depends on r , the two angles in the volume element are integrated)

$$K_{eq} = 4\pi N_A \int_0^\infty r^2 e^{-U(r)/k_B T} dr$$

$U(\xi) \rightarrow$ potential describing the interaction between A and B



$$H_{AB} = \sum_{i=1}^3 \frac{(p_i^{com})^2}{2(m_A + m_B)} + \sum_{i=1}^3 \frac{(p_i^R)^2}{2\mu} + U(\xi) \quad \mu = \frac{m_A \cdot m_B}{(m_A + m_B)}$$

$$q_{AB} = V[2\pi(m_A + m_B)k_B T / h^2]^{3/2} \cdot (2\pi\mu k_B T / h^2)^{3/2} \cdot \int e^{-U(\xi)/k_B T} d\xi$$


Substituting the partition functions in the expression for K_{eq} :

$$K_{eq} = \int e^{-U(r)/k_B T} dx dy dz$$

Mathematical development to obtain affinity constants from PMFs



Cyclodextrin	Neutral		Protonated	
	UP	DOWN	UP	DOWN
SBE7	30	40	$2.0 \cdot 10^4$	$8.2 \cdot 10^3$
SBE6	24	13	$2.3 \cdot 10^4$	$4.0 \cdot 10^3$
SBE5	13	11	$2.3 \cdot 10^3$	$2.1 \cdot 10^3$








Neutral remdesivir Protonated remdesivir



CAPTISOL + REMDESIVIR: AN ORTHOGONAL STUDY

ITC experiments



Parameter	Value	std dev
K_A (M^{-1})	6562	72
DH (cal/mol)	-678	2
r_c	1.905	0.009


AM
AFFINIMETER





CAPTISOL + REMDESIVIR: AN ORTHOGONAL STUDY

Molecular Dynamics simulations





Aggregation studies




A NEW WAY TO SEE...WHAT THE EYES CANNOT SEE


Augmented Reality



Download





Scan



Have fun!




Ollomol AR for Captisol is an Augmented Reality (AR) molecular viewer developed to visualize 3D-AR images of complexes formed by Captisol with the following 12 drugs: allopregnanolone, amiodarone, carbamazepine, aripiprazole, busulfan, delafloxacin, carfilzomib, melphalan, posaconazole, maropitant, voriconazole and ziprasidone mesylate. The 3D-movies were generated by Molecular Dynamics simulations.





A NEW WAY TO SEE...WHAT THE EYES CANNOT SEE

Augmented Reality



Available on the
App Store



Get it on
Google play



A NEW WAY TO SEE...WHAT THE EYES CANNOT SEE


Augmented Reality





A NEW WAY TO SEE...WHAT THE EYES CANNOT SEE

Augmented Reality





A NEW WAY TO SEE...WHAT THE EYES CANNOT SEE



Augmented Reality





A NEW WAY TO SEE...WHAT THE EYES CANNOT SEE

Virtual Reality



mduse.com/coronaviruscoaster/




MD.USE
Innovative Solutions S.L.

ciQUS

Centro Singular de Investigación
en Química Biolóxica e
Materiais Moleculares

USC
UNIVERSIDADE
DE SANTIAGO
DE COMPOSTELA

CAPTISOL[®]
A Ligand TECHNOLOGY



info@mduse.com

Open your eyes...
...to the molecular world